176 related articles for article (PubMed ID: 26082469)
1. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.
Fernández-Nogales M; Hernández F; Miguez A; Alberch J; Ginés S; Pérez-Navarro E; Lucas JJ
Hum Mol Genet; 2015 Sep; 24(17):5040-52. PubMed ID: 26082469
[TBL] [Abstract][Full Text] [Related]
2. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
3. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.
Engel T; Hernández F; Avila J; Lucas JJ
J Neurosci; 2006 May; 26(19):5083-90. PubMed ID: 16687499
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease.
Rippin I; Bonder K; Joseph S; Sarsor A; Vaks L; Eldar-Finkelman H
Neurobiol Dis; 2021 Jul; 154():105336. PubMed ID: 33753290
[TBL] [Abstract][Full Text] [Related]
5. GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions.
L'Episcopo F; Drouin-Ouellet J; Tirolo C; Pulvirenti A; Giugno R; Testa N; Caniglia S; Serapide MF; Cisbani G; Barker RA; Cicchetti F; Marchetti B
Cell Death Dis; 2016 Apr; 7(4):e2206. PubMed ID: 27124580
[TBL] [Abstract][Full Text] [Related]
6. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase-3 reduces acetylcholine level in striatum via disturbing cellular distribution of choline acetyltransferase in cholinergic interneurons in rats.
Zhao L; Chu CB; Li JF; Yang YT; Niu SQ; Qin W; Hao YG; Dong Q; Guan R; Hu WL; Wang Y
Neuroscience; 2013; 255():203-11. PubMed ID: 24121130
[TBL] [Abstract][Full Text] [Related]
8. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
Wade A; Jacobs P; Morton AJ
Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
[TBL] [Abstract][Full Text] [Related]
10. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
Stack EC; Kubilus JK; Smith K; Cormier K; Del Signore SJ; Guelin E; Ryu H; Hersch SM; Ferrante RJ
J Comp Neurol; 2005 Oct; 490(4):354-70. PubMed ID: 16127709
[TBL] [Abstract][Full Text] [Related]
11. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
[TBL] [Abstract][Full Text] [Related]
12. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
13. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
14. Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.
Narayanan KL; Chopra V; Rosas HD; Malarick K; Hersch S
Mol Neurobiol; 2016 May; 53(4):2132-40. PubMed ID: 25941073
[TBL] [Abstract][Full Text] [Related]
15. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease.
Pang TY; Du X; Zajac MS; Howard ML; Hannan AJ
Hum Mol Genet; 2009 Feb; 18(4):753-66. PubMed ID: 19008301
[TBL] [Abstract][Full Text] [Related]
16. Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.
Herbst EA; Holloway GP
Neuroscience; 2015 Sep; 303():515-23. PubMed ID: 26186895
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.
Chiu CT; Liu G; Leeds P; Chuang DM
Neuropsychopharmacology; 2011 Nov; 36(12):2406-21. PubMed ID: 21796107
[TBL] [Abstract][Full Text] [Related]
18. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
[TBL] [Abstract][Full Text] [Related]
19. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice.
Gomez-Sintes R; Bortolozzi A; Artigas F; Lucas JJ
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1524-33. PubMed ID: 25088904
[TBL] [Abstract][Full Text] [Related]
20. 'Super-Enrichment' Reveals Dose-Dependent Therapeutic Effects of Environmental Stimulation in a Transgenic Mouse Model of Huntington's Disease.
Mazarakis NK; Mo C; Renoir T; van Dellen A; Deacon R; Blakemore C; Hannan AJ
J Huntingtons Dis; 2014; 3(3):299-309. PubMed ID: 25300333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
